Plus Therapeutics is pleased to announce its participation in the upcoming Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference, taking place August 14–16, 2025, at the Baltimore Waterfront Marriott Hotel in Baltimore, Maryland.
The company will deliver an oral presentation of new clinical results from its ReSPECT-LM trial, which is evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a rare and aggressive complication of metastatic cancer. In addition to the data presentation, Plus Therapeutics will host a sponsored educational symposium focused on clinical advances in targeted radiotherapeutics for central nervous system (CNS) metastases.
“We’re proud to share new clinical insights from our ReSPECT-LM trial at this important gathering of oncology and neuro-oncology leaders,” said Dr. Marc Hedrick, President & CEO of Plus Therapeutics. “Events like SNO/ASCO provide a critical opportunity to engage with the clinical and research community on new treatment pathways for LM.”
The ReSPECT-LM trial continues to enroll patients and is supported by a $17.6 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Read the full press release for presentation times and symposium details:
View the full announcement
For more about the ReSPECT-LM clinical trial, including eligibility and enrollment details:
Visit respect-trials.com/lm
#PlusTherapeutics #PSTV #ReSPECTLM #REYOBIQ #LeptomeningealMetastases #LMD #CNSMetastases #ClinicalTrials #MetastaticCancer #BreastCancer #LungCancer #Melanoma #SNOASCO2025 #Oncology #NeuroOncology #CancerResearch
Recent Comments